Report Publication Announcement • Mar 22, 2024
Report Publication Announcement
Open in ViewerOpens in native device viewer
Board approval of the 2023 Financial statements for Medistim ASA
(Oslo, 22end of March 2024) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Board of Medistim ASA has approved the Financial Statements for 2023. The Financial Statements are without changes from the preliminary Financial Statements published on the 29th of February 2024. The annual report for 2023 is now available. The Annual General Meeting will be held on 24th of April 2024.
About Medistim:
Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, Canada, China, Sweden and Norway, in addition to the about 60 distributors in Europe, Asia, Middle East, Africa, and South America. For more information, visit the Medistim home page: www.Medistim.com
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.